Prof Kelly-Anne Phillips
@drkellyphillips
Followers
353
Following
257
Media
4
Statuses
96
Medical oncologist focused on prevention and treatment of breast cancer and equity in healthcare. Views my own
Melbourne, Victoria
Joined February 2020
Practice- changing. Olaparib ⬇️ breast cancer recurrence in BRCA1/2 carriers by 42%! It’s time to advocate for BRCA1/2 testing for all newly diagnosed early BC. Thanks to the amazing @BCTrialsANZ team for supporting me as the Australian study chair
nejm.org
Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in pati...
5
19
73
A massively important clinical trial, based on ground breaking science from Professors Lindeman and Visvader and their team at WEHI.
Women with a BRCA1 gene mutation have a 70% risk of developing breast cancer over their lifetime. That's why the BRCA-P clinical trial has the potential to be a gamechanger in breast cancer prevention. Find out more: https://t.co/d4wZmTIknn
#trialssavelives
0
0
3
Congratulations @DrPrachiBhave. So lovely to see your deep passion, energy and enthusiasm for melanoma research recognised with this important award.
Congratulations @DrPrachiBhave, the winner of the Morgan Mansell, Young Victorian of the Year Award 2022, announced at the @Melanoma_MRV Scientific Exchange Meeting tonight.👏👏👏
0
0
3
So important for every woman to know her breast cancer risk, and act on it.
iPrevent is an evidence-based online tool designed to help women understand their breast cancer risk. It also provides information on how to reduce this risk and provides tailored advice on breast cancer screening. For more information visit: https://t.co/9mlPcT0BJV
0
2
14
Online in @Annals_Oncology updated @myESMO guidelines on risk reduction and screening of #cancer in hereditary breast-ovarian cancer syndromes: honored to be part of this important work! @OncoAlert @UniGenova @SanMartino_Ge #UNIGEnonsiferma #bcsm #BRCA
https://t.co/bsY9DVxFL3
annalsofoncology.org
Hereditary breast and ovarian cancer syndrome (HBOC) is clinically defined by family history criteria, and molecularly defined by identification of germline pathogenic variants (PVs) in clinically...
0
13
35
Missed our Q&A this week on the topic of Breast Cancer and Genetics? Here's a link to watch the recording of this fantastic discussion. Thanks to our wonderful panel of speakers for their thoughtful insights and advice. https://t.co/OrQDeNfgzX
0
5
4
Looking forward to discussing the latest advances in hereditary breast cancer with @annabelcrabb @GeoffLindeman @MilitaZaheed and Karen Alexander. Breast Cancer Trials @BCTrialsANZ is leading ground-breaking research in this area. Don’t miss it!
Our next online Q&A will be discussing the topic of Breast Cancer and Genetics. Moderated by Author and Journalist Ms Annabel Crabb, our team of experts will be on hand to answer your questions and provide a research update. Click the link to register. https://t.co/NO3iy6olP5
0
6
17
➡️today @NatureCancer 1. we show in a preclinical model how checkpoint inhibitors can cause ovarian inflammation potentially affecting #fertility #bcsm @OncoAlert Gr8 work w @Huttlab 🙏 @sneha_sant @Lauren_Alesi @amy_winship @PeterMacRes @MonashBDI 👉 https://t.co/h8QfRfKnIV
3
35
116
Well worth a look. Professor Coles is a leading clinical trialist and an excellent communicator. Great at distilling complex information and making it simple.
During BCT's 43rd ASM, we recorded interviews with International Guest Speakers on their research. Charlotte Coles is a Professor of Breast Cancer Clinical Oncology at the University of Cambridge. Click the link to watch Professor Charlotte Coles’ video. https://t.co/iLNFW8cKGQ
0
0
8
One of the humblest, most generous researchers I know. Congratulations Prue, from one of the many whose careers you have quietly facilitated.
Congratulations to Professor Prue Francis on receiving the 2022 Gold Medal! The BCT Gold Medal recognises the outstanding achievements of a member of BCT, who has played an instrumental role in the development of breast cancer clinical trials research. #BCT2022
0
1
29
Eye-opening survey on why physician-industry COI is so common. A "majority simultaneously believed that interactions could influence prescribing while denying influence on their own prescribing" In other words, docs are... https://t.co/uKi2X2BGHX
@JCOOP_ASCO @peterbachmd
1
3
16
🚨Why isn’t ovarian toxicity assessed in breast ca trials? ❗️Clinicians,consumers,pharma, regulatory agencies report ovarian tox is not prioritised during trial design ‼️Ovarian tox info is needed for decision making ✅ We need guidelines and advocacy https://t.co/HiWDeRjgvE
1
3
12
Australian women have spoken. Loudly.
theguardian.com
Climate 200 convenor says ‘people who called themselves moderates didn’t deliver’ while Labor argues election shows ‘teals are eating the Liberal party alive’
0
0
2
A clear reminder to all of us designing cancer clinical trials - don’t forget to collect data on the effect of new anti-cancer drugs on women’s ovarian function! Congratulations @CuiWanda and @LouiseKeoghMDHS for leading this important work
thebreastonline.com
Detailed toxicity data are routinely collected in breast cancer (BC) clinical trials. However, ovarian toxicity is infrequently assessed, despite the adverse impacts on fertility and long-term health...
0
1
7
Hey Twitter, I’m seeking an experienced Personal Assistant to join my dynamic and passionate team focussed on cancer prevention. Applications are open now!
0
2
4
“Within relationships of care, clinicians notice the patient’s situation in “high definition,” and co-create a sensible and minimally disruptive plan of care with each patient, acting with compassion and competence. “ 💯% this
bmj.com
Fuelled by the medicalisation of life and an ever-expanding remit, healthcare has become industrialised and unsustainable. Sustainable healthcare requires a shift from industrial healthcare to...
1
2
5
October is #BreastCancerAwarenessMonth and our incredible team of specialist #breastcancer nurses will be discussing everything you should know over the month, including at a free webinar on October 28. Find out more: https://t.co/v9insubgdV
1
4
17
We understand no one needs to make you aware of breast cancer. We post this for all the survivors, the caregivers, advocates, the grieving, dedicated doctors and researchers, and especially everyone we’ve lost and continue to mourn.
1
20
64
The Penny Taylor Oration, a community forum to improve awareness & action on #ovariancancer will be live streamed this Thurs Sept 23, 12pm Honoured to co-host with @kylie_gorringe @DrLizChristie @DaleGarsed @g_auyeung and to introduce KEYNOTE SPEAKER @ProfClareScott tickets⬇️
Join us for the annual Penny Taylor Oration, a community forum about #OvarianCancer. This year's keynote speaker is medical oncologist and ovarian cancer researcher @ProfClareScott. September 23 at 12pm, get your free tickets at: https://t.co/7ve8fUoOM2
1
10
12
Congratulations to Dr Tamara Hettipathirana who undertook this practice- changing research as her MD research project. It is safe to omit CBE in BRCA1/2 mutation carriers undergoing MRI breast screening- facilitating Telehealth for those who choose. Outstanding work! @PeterMacHSR
Value of clinical breast exam in breast cancer surveillance program for germline BRCA1 or BRCA2 mutations … #freeaccess #research … "Clinical breast exam did not increase number of cancers detected in MRI‐screened women with BRCA1/2" https://t.co/Xtkr7aDLm6 ... #medtwitter
0
1
12
Increased endometrial cancer risk for BRCA1/2 mutation carriers. Another reason to discuss hysterectomy at time of preventive bilateral salpingo-oophorectomy for these women. Congratulations to the HEBON group on this important study.
academic.oup.com
AbstractBackground. Endometrial cancer (EC) risk in BReast CAncer gene 1/2 (BRCA1/2) mutation carriers is uncertain; therefore, we assessed this in a large
0
1
11